TY - JOUR T1 - Current maintenance treatment of chronic obstructive pulmonary disease in China JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P4108 AU - Kewu Huang AU - Chen Wang AU - Jiangna Han AU - Jinping Zheng AU - Lu Dai AU - INTACT Study Investigators Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P4108.abstract N2 - Background: Treatment with long-acting bronchodilators is recommended to control symptoms, reduce exacerbations and improve quality of life in COPD, according to the GOLD 2011 recommendations. In China, the patterns of pharmacological treatment in COPD patients are not known yet.Aims:We investigated the current status of COPD maintenance treatments in China.Methods: 1,634 patients with spirometry diagnosis of COPD from 83 hospitals covering 17 provinces in China have so far been enrolled in the ongoing INTACT study (Indacaterol on Chronic Obstructive Pulmonary Disease maintenance treatment in China). The participants had extensive interviews concerning clinical and demographic data, symptoms as assessed by the mMRC and the CAT, exacerbation history, physician-diagnosed comorbidities, and maintenance medications used at home. Patients were assigned to the GOLD December 2011 groups A, B, C, and D.Results: 10.3% of the overall population was GOLD A; 21% B; 8.4% C and 60.3% D. The current status of COPD maintenance treatments in China are shown below. In GOLD A and GOLD B, 47.6% and 48.5% patients were on ICS/LABA; 23.1% and 25.4% patients triple.View this table:Conclusions: COPD treatment in this sample did not follow the GOLD 2011 recommendations, particularly in A, B, and C patients. ER -